Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of NC-6004 in Combination With 5-FU and Cetuximab as First-line Treatment in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT02817113 is registered in ClinicalTrials.gov with Orient Europharma Co., Ltd. as lead sponsor.

NCT NCT02817113
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02817113 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of NC-6004 in Combination With 5-FU and Cetuximab as First-line Treatment in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
Lead sponsor
Orient Europharma Co., Ltd.
Phase
Phase 1
Overall status
Terminated
Start date
June 30, 2016
Completion date
September 30, 2018
Enrollment
4 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck neoplasms